Neurogene, Inc. Common Stock (NGNE)
PHARMACEUTICAL PREPARATIONS
Neurogene, Inc. Common Stock (NGNE) is listed on Nasdaq, where it has traded since December 19, 2023.
- Listed On
- Nasdaq
- Listed Since
- December 19, 2023
- Employees
- 131
- Market Cap
- $609M
About Neurogene, Inc. Common Stock
Neurogene Inc is a clinical-stage biotechnology company committed to overcoming the limitations of neurological diseases into treatable conditions, by harnessing its proprietary transgene regulation technology, EXACT(Expression Attenuation via Construct Tuning). It is building a differentiated product portfolio of genetic medicines for rare neurological diseases with high unmet needs. The drug candidates in the company's product pipeline include NGN-401, which is in development for the treatment of Rett syndrome, using its EXACT platform, and NGN-101, a non-EXACT, conventional gene therapy development candidate for the treatment of CLN5 Batten disease, designed to deliver the CLN5 gene and packaged in an AAV9 capsid.
Institutional ownership
In 13F filings for the quarter ended June 30, 2026, 108 institutions reported holding NGNE, with 17.3 million shares worth $544.4 million in aggregate. The largest reported holder was Samsara Biocapital, with 1.7 million shares worth $54.0 million. Of the 5 largest holders listed below, 1 added shares, 1 reduced its position and 3 held their positions unchanged during the quarter.
| Institution | Shares | Value | Quarter change |
|---|---|---|---|
| Samsara Biocapital | 1,717,127 | $54M | Unchanged |
| Casdin Capital | 1,545,361 | $49M | Added 8.8% |
| Redmile Group | 1,412,199 | $44M | Reduced 3.25% |
| Rtw Investments | 1,362,456 | $43M | Unchanged |
| Ecor1 Capital | 1,271,342 | $40M | Unchanged |
Form 13F is a quarterly report that institutional investment managers with at least $100 million in qualifying securities file with the SEC. It lists long positions as of the last day of the quarter and is due within 45 days of quarter end, so these holdings describe that date rather than today.
Frequently asked questions
What is NGNE?
Neurogene, Inc. Common Stock (NGNE) is listed on Nasdaq, where it has traded since December 19, 2023.
Who are the largest institutional holders of NGNE?
In 13F filings for the quarter ended June 30, 2026, the largest reported holders of NGNE were Samsara Biocapital, Casdin Capital and Redmile Group.
How many institutions own NGNE?
108 institutions reported a position in NGNE for the quarter ended June 30, 2026, worth $544.4 million in total.
Did institutions buy or sell NGNE last quarter?
Of the 5 largest reported holders, 1 added shares, 1 reduced its position and 3 held their positions unchanged during the quarter. Every reported holder and its change is on the SentiSense ownership page for NGNE.
Every reported institutional holder, plus insider and congressional trades in NGNE, on SentiSense.